Generic Medicine Info
May be taken with or without food.
Special Precautions
Patient with chronic lung disease and diabetes. Immunocompromised or intubated (in ICU setting) patient. Rule out gastric malignancy or possibility of malignancy prior to therapy. Renal impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, headache or confusion, if affected, do not drive or operate machinery. Monitoring Parameters Monitor CBC, gastric pH, liver function (prolonged use), and occult blood with gastrointestinal bleeding.
Adverse Reactions
Blood and lymphatic system disorders: Rarely, Thrombocytopenia, agranulocytosis, pancytopenia, leucopenia. Cardiac disorders: Arrhythmia, atrioventricular block, palpitations. Ear and labyrinth disorders: Tinnitus. Eye disorders: Orbital oedema, conjunctival injection. Gastrointestinal disorders: Constipation, diarrhoea, taste disorder, rarely, dry mouth, nausea, vomiting, abdominal discomfort or distension. General disorders and administration site conditions: Fever, fatigue, asthenia. Hepatobiliary disorders: Cholestatic jaundice, hepatitis. Immune system disorders: Angioedema. Injury, poisoning and procedural complications: Irritation at injection site (IV). Investigations: Increased liver enzymes. Metabolism and nutrition disorders: Anorexia. Musculoskeletal and connective tissue disorders: Musculoskeletal pain including muscle cramps, arthralgia, rhabdomyolysis. Nervous system disorders: Headache, dizziness, paraesthesia. Psychiatric disorders: Insomnia, somnolence, agitation, seizure, psychic disturbances including hallucinations, confusion, agitation, depression, anxiety. Reproductive system and breast disorders: Decreased libido. Respiratory, thoracic and mediastinal disorders: Bronchospasm, rarely, interstitial pneumonia. Skin and subcutaneous tissue disorders: Acne, dry skin, rash, pruritus, urticaria. Rarely, toxic epidermal necrolysis, Stevens-Johnson syndrome. Vascular disorders: Anaphylaxis, flushing.
Drug Interactions
May decrease serum concentrations of atazanavir, cefditoren, delavirdine, ketoconazole, and fosamprenavir. May decrease the absorption of dasatinib. Probenecid inhibits the renal tubular secretion of famotidine. Antacids may reduce the absorption of famotidine.
ATC Classification
A02BA03 - famotidine ; Belongs to the class of H2-receptor antagonists. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Disclaimer: This information is independently developed by CIMS based on famotidine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in